Sobi publishes its Report for the First Quarter 2015
(Thomson Reuters ONE) -
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the
first quarter 2015. Revenues for the quarter totalled SEK 865 M (573). All parts
of the business contributed to the result with ReFacto®, Orfadin® and Kineret®
delivering strong performance.
Business Highlights Q1 2015
* Extended and restructured distribution agreement with Exelixis for Cometriq
* Xiapex approved by the EU Commission for the treatment of Peyronie's disease
* Announced positive top-line efficacy and safety results from phase 3
Alprolix paediatric study (Kids B-LONG)
Financial Highlights Q1 2015 (Q1 2014)
* Total revenue was SEK 865 M (573), an increase of 39 per cent at constant
exchange rates
* Product revenue was SEK 633 M (406), an increase of 40 per cent at constant
exchange rates
* Gross margin was 60 per cent (56)
* EBITA was SEK 172 M (-288)
* Ended the quarter with a cash position of SEK 682 M
"2015 is off to a solid beginning with excellent commercial performance across
the portfolio as well as some successes in our development programmes. Total
revenues were SEK 865 M, an increase of 39 per cent over the prior year in
constant exchange rates, cash flow increased compared to the same period last
year and gross margin was in line with our expectations," said Geoffrey
McDonough, CEO and President. "The positive results of the Kids B-LONG study in
the quarter pave the way for an European filing of Alprolix later this year and
makes an EU approval possible before the end of 2016. During the quarter we
have continued to focus on building a world class haemophilia organisation to
support the launch for the haemophilia products."
Financial Summary
Q1 Q1 Full year
Amounts in SEK M 2015 2014 Change 2014
Total revenues 865 573 51% 2,607
--------------------------------------------------------
Gross profit 519 320 62% 1,548
--------------------------------------------------------
Gross margin 60% 56% 59%
--------------------------------------------------------
EBITA(1) 172 -288 >100% -43
--------------------------------------------------------
EBITA excluding write-offs 172 37 >100% 307
--------------------------------------------------------
EBIT (Operating profit/loss) 102 -358 >100% -325
--------------------------------------------------------
Profit/loss for the period 106 -329 >100% -268
(* )FY 2014 includes write-offs relating to Kiobrina® of SEK 325 M in Q1 and to
Multiferon® of SEK 25 M in 2014.
Outlook 2015 - EBITA expectations clarified
For 2015, Sobi continues to expect total revenues for the full year to be in the
range of SEK 2,800 to 3,000 M, and gross margin to be in the range of 58-60 per
cent. Operating costs are projected to increase as the company continues to
prepare for the planned launch of Elocta. Sobi expects EBITA to be in the range
of SEK 300-400 M.[1] The outlook for 2015 is based on constant exchange rates as
of 19 February 2015, and excludes revenue from the potential European launch of
Elocta.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of
Communications Investor Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46
8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
Sobi announces the information set out in this press release pursuant to the
Swedish Securities Market Act. The information was submitted for publication at
08:00 CET on 6 May 2015.
--------------------------------------------------------------------------------
[1] The original outlook presented on 19 February 2015 stated that "Sobi expects
EBITA to be in line with the adjusted 2014 level."
Sobi_Q1_Report_2015_ENG:
http://hugin.info/134557/R/1919070/687019.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire
[HUG#1919070]
Unternehmensinformation / Kurzprofil:
Datum: 06.05.2015 - 08:02 Uhr
Sprache: Deutsch
News-ID 391233
Anzahl Zeichen: 6112
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 149 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi publishes its Report for the First Quarter 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
